Joint Department of Biomedical Engineering of University of North Carolina - Chapel Hill and North Carolina State University, Raleigh, North Carolina, USA.
Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
J Thromb Haemost. 2022 Dec;20(12):2909-2920. doi: 10.1111/jth.15882. Epub 2022 Oct 5.
Thrombogenicity is a known complication of COVID-19, resulting from SARS-CoV-2 infection, with significant effects on morbidity and mortality.
We aimed to better understand the effects of COVID-19 on fibrinogen and the resulting effects on clot structure, formation, and degradation.
Fibrinogen isolated from COVID-19 patients and uninfected subjects was used to form uniformly concentrated clots (2 mg/ml), which were characterized using confocal microscopy, scanning electron microscopy, atomic force microscopy, and endogenous and exogenous fibrinolysis assays. Neuraminidase digestion and subsequent NANA assay were used to quantify sialic acid residue presence; clots made from the desialylated fibrinogen were then assayed similarly to the original fibrinogen clots.
Clots made from purified fibrinogen from COVID-19 patients were shown to be significantly stiffer and denser than clots made using fibrinogen from noninfected subjects. Endogenous and exogenous fibrinolysis assays demonstrated that clot polymerization and degradation dynamics were different for purified fibrinogen from COVID-19 patients compared with fibrinogen from noninfected subjects. Quantification of sialic acid residues via the NANA assay demonstrated that SARS-CoV-2-positive fibrinogen samples contained significantly more sialic acid. Desialylation via neuraminidase digestion resolved differences in clot density. Desialylation did not normalize differences in polymerization, but did affect rate of exogenous fibrinolysis.
These differences noted in purified SARS-CoV-2-positive clots demonstrate that structural differences in fibrinogen, and not just differences in gross fibrinogen concentration, contribute to clinical differences in thrombotic features associated with COVID-19. These structural differences are at least in part mediated by differential sialylation.
血栓形成是 COVID-19 的已知并发症,由 SARS-CoV-2 感染引起,对发病率和死亡率有重大影响。
我们旨在更好地了解 COVID-19 对纤维蛋白原的影响,以及由此对血栓结构、形成和降解的影响。
使用从 COVID-19 患者和未感染的受试者中分离的纤维蛋白原形成均匀浓缩的凝块(2mg/ml),使用共聚焦显微镜、扫描电子显微镜、原子力显微镜以及内源性和外源性纤维蛋白溶解测定来对其进行特征分析。使用神经氨酸酶消化和随后的 NANA 测定来定量唾液酸残基的存在;然后对去唾液酸化的纤维蛋白原制成的凝块进行与原始纤维蛋白原凝块类似的测定。
从 COVID-19 患者纯化的纤维蛋白原制成的凝块比使用非感染受试者的纤维蛋白原制成的凝块明显更硬和更致密。内源性和外源性纤维蛋白溶解测定表明,与非感染受试者的纤维蛋白原相比,来自 COVID-19 患者的纯化纤维蛋白原的聚合和降解动力学不同。通过 NANA 测定对唾液酸残基进行定量,表明 SARS-CoV-2 阳性纤维蛋白原样本中含有明显更多的唾液酸。通过神经氨酸酶消化进行去唾液酸化解决了凝块密度的差异。去唾液酸化不能使聚合的差异正常化,但确实影响外源性纤维蛋白溶解的速度。
在纯化的 SARS-CoV-2 阳性凝块中观察到的这些差异表明,纤维蛋白原的结构差异,而不仅仅是纤维蛋白原浓度的差异,导致与 COVID-19 相关的血栓形成特征的临床差异。这些结构差异至少部分由差异唾液酸化介导。